Insmed (INSM) Earnings Narrow Losses As Fair Value Comes Back Into Focus
Insmed earnings event and why the stock is on watch
Insmed (INSM) has drawn fresh attention after reporting second quarter 2026 results that showed a much smaller net loss than a year earlier, with both net loss and loss per share narrowing sharply.
See our latest analysis for Insmed.
The earnings release appears to have shifted sentiment around Insmed, with the 1 day share price return of 3.7% adding to a 30 day share price return of 18.46%. However, the year to date share price return is still down 27.55% and the 3 year total shareholder return is very large.
If you are looking for other ideas in healthcare, this is a useful moment to see what is moving across 40 healthcare AI stocks.
Insmed shares have bounced on the earnings surprise, yet the stock still trades well below both analyst targets and some intrinsic value estimates. So where might fair value really sit, given that kind of gap in expectations?
Most Popular Narrative: 34.9% Undervalued
At a last close of $128.32 versus a most-followed fair value estimate of about $197.14, Insmed is framed as materially undervalued by that narrative, which leans heavily on its respiratory and rare disease pipeline.
The anticipated U.S. launch of brensocatib in bronchiectasis in the third quarter of 2025 is a major catalyst, expected to significantly increase revenue once it hits the market and starts generating sales late in Q3. The upcoming Phase II data for TPIP in PAH by mid-2025 and brensocatib in CRS without nasal polyps by the end of 2025 are key clinical milestones that could enhance future revenue streams if positive.
Want to see how aggressive revenue growth, rising margins and a premium future earnings multiple combine into that $197.14 fair value for Insmed? The narrative connects ambitious top line targets and a shift to profitability with a valuation framework that treats the company more like a high growth compounder than a loss making biotech today.
Result: Fair Value of $197.14 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Insmed's story still carries important risks, including potential delays to brensocatib approvals and payer pushback that could slow real world uptake and revenue progress.
Find out about the key risks to this Insmed narrative.
Another View on Insmed’s Valuation
The popular narrative paints Insmed as about 34.9% undervalued, yet the SWS DCF model suggests something even more extreme. On that framework, Insmed at $128.32 trades about 70.6% below an estimated future cash flow value of $436.60, which implies a very different gap. Which set of assumptions appears more realistic to you?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
If this Insmed story feels finely balanced between promise and concern, take a moment to review the data and decide where you stand. To help frame both sides of the debate, check out the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Insmed?
Do not stop with Insmed. Use this momentum to widen your watchlist and find other stocks that fit your style before the next move passes you by.
- Target reliable income streams by scanning for companies that show strong yields and resilience using the 10 dividend fortresses.
- Hunt for quality at a fair price by checking stocks that combine solid fundamentals with attractive valuations through the screener containing 19 high quality undiscovered gems.
- Prioritise peace of mind by focusing on businesses that carry lower overall risk scores with the 80 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com